HIMS 241108 28.50C (HIMS241108C28500) Stock Options, News & Quotes

US OptionsDetailed Quotes

HIMS241108C28500

Watchlist

0.05
-0.20-80.00%

15min DelayClose Nov 5 16:00 ET

0.05High0.03Low

Intraday

5D
Daily

News

Hims & Hers Health Options Spot-On: On November 5th, 162.7K Contracts Were Traded, With 342.86K Open Interest
Moomoo News16:30 ET
Hims & Hers Stock Rises on Earnings and Planned Generic Version of Novo Nordisk Diabetes Drug -- Barrons.com
Barron's11:38 ET
What's Going On With Hims & Hers Health Stock Tuesday?
Benzinga11:01 ET
Hims & Hers Core Business Looked Strong in 3Q -- Market Talk
WSJNov 5 10:37 ET
Hims & Hers Still Benefiting From Unmet GLP-1 Demand -- Market Talk
WSJNov 5 10:19 ET
Express News | Top 10 Trending Stocks On WallStreetBets As Of November 5, 2024 (Via Swaggy Stocks)
BenzingaNov 5 09:32 ET

Comments

topcing

11 hours ago

$Hims & Hers Health (HIMS.US)$ great buy

10351974

13 hours ago

reclimb

Share Your Profit/Loss

frogoracletrading

Yesterday 09:50

$HIMS Support / Resistance Levels

Nice move up on earnings. Watch for the GAP to be tested tomorrow.
Larger Image: tradingview.com...
$Hims & Hers Health (HIMS.US)$

Trytosaveabit

Yesterday 06:24

Hmm

$Hims & Hers Health (HIMS.US)$ On conference call Hims & Hers Health Says It Plans to Bring Liraglutide the First Generic GLP-1 in the Market to the Platform in 2025?

Trytosaveabit

Yesterday 05:25

Nice

$Hims & Hers Health (HIMS.US)$ & Hers Health, Inc. Reports Third Quarter 2024 Financial Results
Revenue of $401.6 million, up 77% year-over-year in Q3 2024
Net income of $75.6 million; Adjusted EBITDA of $51.1 million in Q3 2024
Subscribers grew to 2.0 million, up 44% year-over-year in Q3 2024
Raises full year 2024 revenue guidance to a range of $1.460 billion to $1.465 billion and Adjusted EBITDA guidance to a range of $173 million to $178 million